Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.
Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.
Aptevo Therapeutics (NASDAQ:APVO) has adopted a limited duration stockholder rights plan to protect its interests and those of its shareholders. Effective from November 8, 2020, the plan will distribute one right for each share of common stock, with a record date of November 23, 2020. The rights become exercisable if a person or group acquires 10% or more of the company's stock without Board approval, allowing existing shareholders to purchase additional shares at a favorable valuation. The plan is set to expire on November 8, 2021.
Aptevo Therapeutics announced significant progress in its ongoing APVO436 Phase 1 clinical trial for treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). A patient in cohort 6 achieved complete remission, with bone marrow blasts decreasing from 29% to 0% after two cycles of treatment. As dosing continues in cohort 7, pharmacokinetic modeling suggests dosing in cohorts 5-8 may yield further clinical responses. Aptevo’s ADAPTIR™ technology is highlighted as a more convenient and cost-effective option compared to traditional CAR-T therapies.
Aptevo Therapeutics (NASDAQ:APVO) announced progress in its APVO436 Phase 1/1b clinical trial, with two patients dosed in cohort 7. A total of 30 patients have been treated, showing no dose-limiting toxicities or drug-induced anti-drug antibodies to date. Preliminary evidence suggested clinical responses in some patients, particularly in cohort 4, which is noteworthy despite one patient's disease progression. The trial is entering a critical stage, with dosing now in a therapeutic range, enhancing prospects for clinical activity.
Aptevo Therapeutics (NASDAQ: APVO) released its second quarter 2020 financial results, reporting a net loss of $6.8 million or $2.10 per share, a significant decrease from a $13.3 million loss in Q2 2019. The company generated $0.5 million in royalty revenue from Pfizer's RUXIENCE sales, marking its entry into non-dilutive revenue streams. Cash and equivalents stood at $10.2 million, bolstered by a $25 million loan, ensuring operations through Q3 2021. Clinical developments include completion of cohort 6 in the APVO436 trial for AML and high-grade MDS, with promising preclinical data for ALG.APV-527.
Aptevo Therapeutics (NASDAQ: APVO) announced advancements in its clinical trial for APVO436 treating Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS), completing cohort 6 enrollment. The company reported $0.5 million in royalty revenue from Pfizer's RUXIENCE sales and extended its cash runway into Q3 2021 through a $25 million loan. The net loss narrowed to $6.8 million in Q2 2020 from $13.3 million in Q2 2019. Preclinical data for ALG.APV-527 suggests a favorable safety profile, with further development opportunities being explored.